Prediction of Resistance to Small Molecule FLT3 Inhibitors
暂无分享,去创建一个
Doriano Fabbro | Peter Marynen | Pascal Furet | Jan Cools | D. Fabbro | P. Marynen | P. Furet | J. Griffin | D. Gilliland | J. Cools | N. Mentens | Nicole Mentens | James D Griffin | D Gary Gilliland | Jennifer J. Clark | Jennifer J Clark
[1] J. Radich,et al. The role of FLT3 in haematopoietic malignancies , 2003, Nature Reviews Cancer.
[2] D. Goeddel,et al. Random PCR mutagenesis screening of secreted proteins by direct expression in mammalian cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[3] M. Heinrich,et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] J. Kuriyan,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.
[5] D. Fabbro,et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. , 2003, Cancer cell.
[6] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[7] G. Mcmahon,et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. , 2002, Blood.
[8] L. Toledo,et al. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. , 2000, Structure.
[9] G Vriend,et al. WHAT IF: a molecular modeling and drug design program. , 1990, Journal of molecular graphics.
[10] Doriano Fabbro,et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.
[11] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[12] H. Kantarjian,et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. , 2004, Blood.
[13] Donna Neuberg,et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). , 2002, Cancer cell.
[14] J. Griffin,et al. The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.
[15] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[16] T. Clackson,et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. , 2004, Blood.
[17] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[18] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[19] B. Smith,et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. , 2002, Blood.
[20] Peter Marynen,et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.